Klaria Pharma

Summary of the report

Fourth quarter of 2024

The group in total

- Net sales 1.1 MSEK (1.3 MSEK)

- Other income 0.0 MSEK (0.3 MSEK)

- R&D expenses for the quarter amounted to 9.3 MSEK (1.9 MSEK)

- Profit after tax amounted to -15.6 MSEK (-9.5 MSEK)

- Earnings per share for the quarter amounted to -0.11 SEK (-0.09 SEK)

- Cash flow from operating activities amounted to 1.0 MSEK (9.5 MSEK)

- Liquid assets on the balance sheet date amounted to 0.6 MSEK (1.2 MSEK)

- Equity as of December 31 amounted to 3.3 MSEK (41.1 MSEK)

The period January- December 2024

The group in total

- Net sales 2.2 MSEK (8.5 MSEK)

- Other income 0.1 MSEK (0.5 MSEK)

- R&D expenses for the period amounted to 22.1 MSEK (24.9 MSEK)

- Profit after tax amounted to -47.8 MSEK (-35.8 MSEK)

- Earnings per share for the period amounted to -0.38 SEK (-0.36 SEK)

- Cash flow from operating activities amounted to -12.0 MSEK (-9.1 MSEK)